FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Pharmacokinetic modelling of orally administered cannabidiol...
Frontiers in veterinary science2023; 10; 1234551; doi: 10.3389/fvets.2023.1234551

Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses.

Abstract: Cannabidiol (CBD) products gain increasing popularity amongst animal owners and veterinarians as an alternative remedy for treatment of stress, inflammation or pain in horses. Whilst the use of cannabinoids is banned in equine sports, there is limited information available concerning CBD detection times in blood or urine. The aim of this study was to determine the pharmacokinetic properties of CBD following oral administration in the horse to assist doping control laboratories with interpreting CBD analytical results. Part 1: dose escalation study: Single oral administration of three escalating doses of CBD paste (0.2 mg/kg,  = 3 horses; 1 mg/kg,  = 3; 3 mg/kg,  = 5) with >7 days wash-out periods in between. Part 2: multiple dose study: oral administration of CBD paste (3 mg/kg,  = 6) twice daily for 15 days. Multiple blood and urine samples were collected daily throughout both studies. Following study part 2, blood and urine samples were collected for 2 weeks to observe the elimination phase. Concentrations of CBD, its metabolites and further cannabinoids were evaluated using gas-chromatography/tandem-mass-spectrometry. Pharmacokinetic parameters were assessed via two approaches: population pharmacokinetic analysis using a nonlinear mixed-effects model and non-compartmental analysis. AUC and were tested for dose proportionality. During the elimination phase, the CBD steady-state urine to serum concentration ratio (Rss) was calculated. Oral CBD medication was well-tolerated in horses. Based on population pharmacokinetics, a three-compartment model with zero-order absorption most accurately described the pharmacokinetic properties of CBD. High volumes of distribution into peripheral compartments and high concentrations of 7-carboxy-CBD were observed in serum. Non-compartmental analysis identified a of 12.17 ± 2.08 ng/mL after single administration of CBD (dose: 3 mg/kg). AUC showed dose proportionality, increase for leveled off at higher doses. Following multiple doses, the CBD terminal half-life was 161.29 ± 43.65 h in serum. Rss was 4.45 ± 1.04. CBD is extensively metabolized and shows high volumes of tissue distribution with a resulting extended elimination phase. Further investigation of the potential calming and anti-inflammatory effects of CBD are required to determine cut-off values for medication control using the calculated Rss.
Copyright © 2023 Eichler, Poźniak, Machnik, Schenk, Wingender, Baudisch, Thevis, Bäumer, Lischer and Ehrle.
Get Full Text
Publication Date: 2023-08-09 PubMed ID: 37621871PubMed Central: PMC10445762DOI: 10.3389/fvets.2023.1234551Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article explores how cannabidiol (CBD), is metabolized and distributed in the body of horses, particularly its detection rate in serum and urine, to assist with doping control.

Overview of the Study

  • The study aimed to explore the pharmacokinetic properties of CBD, a non-psychoactive derivative of cannabis, following oral administration in horses. This was encouraged by the rising use of CBD as a substitute therapy for stress, inflammation, or pain relief in horses.
  • A major part of this research was to assist doping control laboratories with the interpretation of CBD analytical results, given that cannabinoids are prohibited in equestine sports.
  • The study was divided into two parts: a dose escalation study, and a multiple dose study.

Dose Escalation Study

  • In the first part of the study, three escalating dosages of CBD paste (0.2 mg/kg, 1 mg/kg, 3 mg/kg) were administered orally to horses. There were seven days wash-out periods between each administration.
  • In the case of any adverse side effects, the amount of CBD administered was reduced.

Multiple Dose Study

  • The second part of the study involved the oral administration of CBD paste (3mg/kg) twice daily for 15 days to another group of horses.
  • Multiple blood and urine samples were collected daily throughout both parts of the study for analyses.
  • Post completion of the second part, blood and urine samples were collected for the next two weeks to observe the elimination phase of CBD.

Findings

  • After analyzing the data using gas-chromatography/tandem-mass spectrometry, it was found that oral CBD was well tolerated in horses. The study reported high volumes of distribution into peripheral compartments and significant concentrations of 7-carboxy-CBD in serum.
  • Non-compartmental analysis showed mean peak concentration of CBD (12.17 ng/mL) after single administration of the dosage (3 mg/kg).
  • The pharmacokinetic properties of CBD were most accurately described by a three-compartment model with zero-order absorption.
  • Following multiple doses, the CBD terminal half-life was 161.29 hours in serum.
  • The research showed high volumes of tissue distribution and extensive metabolism of CBD in horses, leading to an extended elimination phase with a resultant steady-state urine to serum concentration ratio (Rss) of 4.45.

Implications

  • Given the findings, more research is needed to understand the calming and anti-inflammatory effects of CBD and to determine the cut-off values for medication control using the calculated Rss.
  • This study could provide crucial information to doping control laboratories for understanding and interpreting CBD analytical results, hence making a notable contribution to the science of animal doping control.

Cite This Article

APA
Eichler F, Poźniak B, Machnik M, Schenk I, Wingender A, Baudisch N, Thevis M, Bäumer W, Lischer C, Ehrle A. (2023). Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses. Front Vet Sci, 10, 1234551. https://doi.org/10.3389/fvets.2023.1234551

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 10
Pages: 1234551
PII: 1234551

Researcher Affiliations

Eichler, Fabienne
  • Equine Clinic, Veterinary Hospital Freie Universität Berlin, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
Poźniak, Błażej
  • Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Wrocław, Poland.
Machnik, Marc
  • Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
Schenk, Ina
  • Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
Wingender, Anke
  • Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
Baudisch, Natalie
  • Equine Clinic, Veterinary Hospital Freie Universität Berlin, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
Thevis, Mario
  • Center for Preventive Doping Research, Institute of Biochemistry, German Sport University Cologne, Cologne, Germany.
Bäumer, Wolfgang
  • Institute of Pharmacology and Toxicology, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
Lischer, Christoph
  • Equine Clinic, Veterinary Hospital Freie Universität Berlin, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
Ehrle, Anna
  • Equine Clinic, Veterinary Hospital Freie Universität Berlin, School of Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 67 references
  1. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.. JAMA 2015 Jun 23-30;313(24):2456-73.
    doi: 10.1001/jama.2015.6358pubmed: 26103030google scholar: lookup
  2. Ebbert JO, Scharf EL, Hurt RT. Medical Cannabis.. Mayo Clin Proc 2018 Dec;93(12):1842-1847.
    doi: 10.1016/j.mayocp.2018.09.005pubmed: 30522595google scholar: lookup
  3. Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M. US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions.. Front Vet Sci 2018;5:338.
    doi: 10.3389/fvets.2018.00338pmc: PMC6338022pubmed: 30687726google scholar: lookup
  4. Kogan LR, Hellyer PW, Silcox S, Schoenfeld-Tacher R. Canadian dog owners' use and perceptions of cannabis products.. Can Vet J 2019 Jul;60(7):749-755.
    pmc: PMC6563876pubmed: 31281193
  5. Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.. Biomolecules 2020 Feb 11;10(2).
    doi: 10.3390/biom10020279pmc: PMC7072526pubmed: 32054131google scholar: lookup
  6. Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond.. Nat Rev Neurosci 2014 Nov;15(11):757-64.
    doi: 10.1038/nrn3811pubmed: 25315390google scholar: lookup
  7. Pertwee RG. Cannabinoid pharmacology: the first 66 years.. Br J Pharmacol 2006 Jan;147 Suppl 1(Suppl 1):S163-71.
    doi: 10.1038/sj.bjp.0706406pmc: PMC1760722pubmed: 16402100google scholar: lookup
  8. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol--recent advances.. Chem Biodivers 2007 Aug;4(8):1678-92.
    doi: 10.1002/cbdv.200790147pubmed: 17712814google scholar: lookup
  9. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.. Trends Pharmacol Sci 2009 Oct;30(10):515-27.
    doi: 10.1016/j.tips.2009.07.006pubmed: 19729208google scholar: lookup
  10. Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids.. Br J Clin Pharmacol 2018 Nov;84(11):2477-2482.
    doi: 10.1111/bcp.13710pmc: PMC6177698pubmed: 30001569google scholar: lookup
  11. Pacher P, Mukhopadhyay P, Mohanraj R, Godlewski G, Bátkai S, Kunos G. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.. Hypertension 2008 Oct;52(4):601-7.
    doi: 10.1161/HYPERTENSIONAHA.105.063651pmc: PMC2568884pubmed: 18779440google scholar: lookup
  12. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players.. AAPS J 2006 Apr 28;8(2):E298-306.
    doi: 10.1007/BF02854900pmc: PMC3231556pubmed: 16796380google scholar: lookup
  13. Genovese T, Cordaro M, Siracusa R, Impellizzeri D, Caudullo S, Raffone E, Macrí F, Interdonato L, Gugliandolo E, Interlandi C, Crupi R, D'Amico R, Fusco R, Cuzzocrea S, Di Paola R. Molecular and Biochemical Mechanism of Cannabidiol in the Management of the Inflammatory and Oxidative Processes Associated with Endometriosis.. Int J Mol Sci 2022 May 12;23(10).
    doi: 10.3390/ijms23105427pmc: PMC9141153pubmed: 35628240google scholar: lookup
  14. Gugliandolo E, Licata P, Peritore AF, Siracusa R, D'Amico R, Cordaro M, Fusco R, Impellizzeri D, Di Paola R, Cuzzocrea S, Crupi R, Interlandi CD. Effect of Cannabidiol (CBD) on Canine Inflammatory Response: An Ex Vivo Study on LPS Stimulated Whole Blood.. Vet Sci 2021 Sep 4;8(9).
    doi: 10.3390/vetsci8090185pmc: PMC8473042pubmed: 34564578google scholar: lookup
  15. Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA. Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.. Can J Vet Res 2018 Jul;82(3):178-183.
    pmc: PMC6038832pubmed: 30026641
  16. Gamble LJ, Boesch JM, Frye CW, Schwark WS, Mann S, Wolfe L, Brown H, Berthelsen ES, Wakshlag JJ. Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.. Front Vet Sci 2018;5:165.
    doi: 10.3389/fvets.2018.00165pmc: PMC6065210pubmed: 30083539google scholar: lookup
  17. Vaughn DM, Paulionis LJ, Kulpa JE. Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs.. Am J Vet Res 2021 May;82(5):405-416.
    doi: 10.2460/ajvr.82.5.405pubmed: 33904801google scholar: lookup
  18. Potschka H, Bhatti SFM, Tipold A, McGrath S. Cannabidiol in canine epilepsy.. Vet J 2022 Dec;290:105913.
    doi: 10.1016/j.tvjl.2022.105913pubmed: 36209995google scholar: lookup
  19. Corsato Alvarenga I, Panickar KS, Hess H, McGrath S. Scientific Validation of Cannabidiol for Management of Dog and Cat Diseases.. Annu Rev Anim Biosci 2023 Feb 15;11:227-246.
    doi: 10.1146/annurev-animal-081122-070236pubmed: 36790884google scholar: lookup
  20. Miranda-Cortés A, Mota-Rojas D, Crosignani-Outeda N, Casas-Alvarado A, Martínez-Burnes J, Olmos-Hernández A, Mora-Medina P, Verduzco-Mendoza A, Hernández-Ávalos I. The role of cannabinoids in pain modulation in companion animals.. Front Vet Sci 2022;9:1050884.
    doi: 10.3389/fvets.2022.1050884pmc: PMC9848446pubmed: 36686189google scholar: lookup
  21. Mogi C, Yoshida M, Kawano K, Fukuyama T, Arai T. Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases.. Can Vet J 2022 Apr;63(4):423-426.
    pmc: PMC8922375pubmed: 35368394
  22. Loewinger M, Wakshlag JJ, Bowden D, Peters-Kennedy J, Rosenberg A. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis.. Vet Dermatol 2022 Aug;33(4):329-e77.
    doi: 10.1111/vde.13077pmc: PMC9543248pubmed: 35644533google scholar: lookup
  23. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.. J Am Vet Med Assoc 2019 Jun 1;254(11):1301-1308.
    doi: 10.2460/javma.254.11.1301pubmed: 31067185google scholar: lookup
  24. Ellis KL, Contino EK. Treatment using cannabidiol in a horse with mechanical allodynia. Equine Vet Educ (2021) 33:33.
    doi: 10.1111/eve.13168google scholar: lookup
  25. McIver VC, Tsang AS, Symonds NE, Perkins NR, Uquillas E, Dart CM, Jeffcott LB, Dart AJ. Effects of topical treatment of cannabidiol extract in a unique manuka factor 5 manuka honey carrier on second intention wound healing on equine distal limb wounds: a preliminary study.. Aust Vet J 2020 Jun;98(6):250-255.
    doi: 10.1111/avj.12932pubmed: 32096215google scholar: lookup
  26. Cunha RZ, Felisardo LL, Salamanca G, Marchioni GG, Neto OI, Chiocchetti R. The use of cannabidiol as a novel treatment for oral stereotypic behaviour (crib-biting) in a horse.. Vet Anim Sci 2023 Mar;19:100289.
    doi: 10.1016/j.vas.2023.100289pmc: PMC9941357pubmed: 36824298google scholar: lookup
  27. Landa L, Trojan V, Demlova R, Jurica J, Hrib R. Cannabidiol and the possibilities of its use in veterinary medicine of dogs and horses: a brief review. Vet Med (2022) 67:455–62.
    doi: 10.17221/127/2021-VETMEDgoogle scholar: lookup
  28. Williams MR, Holbrook TC, Maxwell L, Croft CH, Ientile MM, Cliburn K. Pharmacokinetic Evaluation of a Cannabidiol Supplement in Horses.. J Equine Vet Sci 2022 Mar;110:103842.
    doi: 10.1016/j.jevs.2021.103842pubmed: 34923070google scholar: lookup
  29. Ryan D, McKemie DS, Kass PH, Puschner B, Knych HK. Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses.. Drug Test Anal 2021 Jul;13(7):1305-1317.
    doi: 10.1002/dta.3028pubmed: 33723919google scholar: lookup
  30. Yocom AF, O'Fallon ES, Gustafson DL, Contino EK. Pharmacokinetics, Safety, and Synovial Fluid Concentrations of Single- and Multiple-Dose Oral Administration of 1 and 3 mg/kg Cannabidiol in Horses.. J Equine Vet Sci 2022 Jun;113:103933.
    doi: 10.1016/j.jevs.2022.103933pubmed: 35307550google scholar: lookup
  31. Turner SE, Knych HK, Adams AA. Pharmacokinetics of cannabidiol in a randomized crossover trial in senior horses.. Am J Vet Res 2022 Jul 18;83(9).
    doi: 10.2460/ajvr.22.02.0028pubmed: 35895770google scholar: lookup
  32. Draeger AL, Hoffman LK, Godwin PR, Davis AJ, Porr SA. Pharmacokinetics of a single feeding of pelleted cannabidiol in horses. Steeplechase (2020):4: 1.
  33. Sánchez de Medina A, Serrano-Rodríguez JM, Díez de Castro E, García-Valverde MT, Saitua A, Becero M, Muñoz A, Ferreiro-Vera C, Sánchez de Medina V. Pharmacokinetics and oral bioavailability of cannabidiol in horses after intravenous and oral administration with oil and micellar formulations.. Equine Vet J 2023 Nov;55(6):1094-1103.
    doi: 10.1111/evj.13923pubmed: 36624043google scholar: lookup
  34. Mercer MA, Davis JL. Cannabinoids in veterinary medicine: is there evidence to support the trend?. Equine Vet Educ (2021) 33:177–9.
    doi: 10.1111/eve.13199google scholar: lookup
  35. Turner S, Knych HK, Adams AA. The effects of cannabidiol on immune function and health parameters in senior horses.. Vet Immunol Immunopathol 2023 Mar;257:110549.
    doi: 10.1016/j.vetimm.2023.110549pubmed: 36682327google scholar: lookup
  36. Fédération Equestre Internationale. FEI clean sport—prohibited substances database. (2022).
  37. Deutsche Reiterliche Vereinigung. Anti-Doping und Medikation im Pferdesport. (2022).
  38. Johansson E, Norén K, Sjövall J, Halldin MM. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry.. Biomed Chromatogr 1989 Jan;3(1):35-8.
    doi: 10.1002/bmc.1130030109pubmed: 2539872google scholar: lookup
  39. You Y, Proctor RM, Vasilko ED, Robinson MA. Doping control analysis of four JWH-250 metabolites in equine urine by liquid chromatography-tandem mass spectrometry.. Drug Test Anal 2019 May;11(5):649-658.
    doi: 10.1002/dta.2542pubmed: 30423218google scholar: lookup
  40. Mareck U, Fusshöller G, Geyer H, Huestis MA, Scheiff AB, Thevis M. Preliminary data on the potential for unintentional antidoping rule violations by permitted cannabidiol (CBD) use.. Drug Test Anal 2021 Mar;13(3):539-549.
    doi: 10.1002/dta.2959pubmed: 33125823google scholar: lookup
  41. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics.. Annu Rev Pharmacol Toxicol 1992;32:185-209.
    doi: 10.1146/annurev.pa.32.040192.001153pubmed: 1605567google scholar: lookup
  42. Wang J, Schneider BK, Sun P, Gong X, Qiu J, Li J, Seo YJ, Mochel JP, Cao X. Nonlinear mixed-effects pharmacokinetic modeling of the novel COX-2 selective inhibitor vitacoxib in dogs.. J Vet Pharmacol Ther 2019 Sep;42(5):530-540.
    doi: 10.1111/jvp.12802pubmed: 31369157google scholar: lookup
  43. Petkova T, Milanova A, Poźniak B. The effects of cyclosporine A or activated charcoal co-administration on the pharmacokinetics of enrofloxacin in chickens.. Poult Sci 2023 Jan;102(1):102225.
    doi: 10.1016/j.psj.2022.102225pmc: PMC9646970pubmed: 36343435google scholar: lookup
  44. Pelligand L, Soubret A, King JN, Elliott J, Mochel JP. Modeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in Cats.. CPT Pharmacometrics Syst Pharmacol 2016 Nov;5(11):625-635.
    doi: 10.1002/psp4.12141pmc: PMC5193001pubmed: 27770596google scholar: lookup
  45. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J (1995) 29:1039–48.
    doi: 10.1177/009286159502900324google scholar: lookup
  46. Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion.. Pharm Stat 2009 Jan-Mar;8(1):38-49.
    doi: 10.1002/pst.326pubmed: 18386766google scholar: lookup
  47. Toutain PL, Lassourd V. Pharmacokinetic/pharmacodynamic approach to assess irrelevant plasma or urine drug concentrations in postcompetition samples for drug control in the horse.. Equine Vet J 2002 May;34(3):242-9.
    doi: 10.2746/042516402776185985pubmed: 12108741google scholar: lookup
  48. Machnik M, Kaiser S, Koppe S, Kietzmann M, Schenk I, Düe M, Thevis M, Schänzer W, Toutain PL. Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations.. Drug Test Anal 2017 Sep;9(9):1372-1384.
    doi: 10.1002/dta.2097pubmed: 27662634google scholar: lookup
  49. Leise JM, Leatherwood JL, Paris BL, Walter KW, George JM, Martinez RE, Glass KP, Lo CP, Mays TP, Wickersham TA. Evaluation of an Oral Supplemental Cannabidiol Product for Acceptability and Performance in Mature Horses.. Animals (Basel) 2023 Jan 10;13(2).
    doi: 10.3390/ani13020245pmc: PMC9854761pubmed: 36670785google scholar: lookup
  50. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats.. Animals (Basel) 2019 Oct 19;9(10).
    doi: 10.3390/ani9100832pmc: PMC6826847pubmed: 31635105google scholar: lookup
  51. Samara E, Bialer M, Mechoulam R. Pharmacokinetics of cannabidiol in dogs.. Drug Metab Dispos 1988 May-Jun;16(3):469-72.
    pubmed: 2900742
  52. Tittle D, Wakshlag J, Schwark W, Lyubimov A, Zakharov A, Gomez B. Twenty-four hour and one-week steady state pharmacokinetics of cannabinoids in two formulations of cannabidiol and xannabidiolic acid rich hemp in dogs. Med Res Arch (2022) 10:10.
    doi: 10.18103/mra.v10i7.2907google scholar: lookup
  53. Wang T, Zakharov A, Gomez B, Lyubimov A, Trottier NL, Schwark WS, Wakshlag JJ. Serum Cannabinoid 24 h and 1 Week Steady State Pharmacokinetic Assessment in Cats Using a CBD/CBDA Rich Hemp Paste.. Front Vet Sci 2022;9:895368.
    doi: 10.3389/fvets.2022.895368pmc: PMC9355628pubmed: 35937287google scholar: lookup
  54. Della Rocca G, Paoletti F, Conti MB, Galarini R, Chiaradia E, Sforna M, Dall'Aglio C, Polisca A, Di Salvo A. Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs.. Front Vet Sci 2022;9:1104152.
    doi: 10.3389/fvets.2022.1104152pmc: PMC9859632pubmed: 36686155google scholar: lookup
  55. Wakshlag JJ, Schwark WS, Deabold KA, Talsma BN, Cital S, Lyubimov A, Iqbal A, Zakharov A. Pharmacokinetics of Cannabidiol, Cannabidiolic Acid, Δ9-Tetrahydrocannabinol, Tetrahydrocannabinolic Acid and Related Metabolites in Canine Serum After Dosing With Three Oral Forms of Hemp Extract.. Front Vet Sci 2020;7:505.
    doi: 10.3389/fvets.2020.00505pmc: PMC7498943pubmed: 33102539google scholar: lookup
  56. Perucca E, Bialer M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications.. CNS Drugs 2020 Aug;34(8):795-800.
    doi: 10.1007/s40263-020-00741-5pubmed: 32504461google scholar: lookup
  57. Kicman A, Toczek M. The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease.. Int J Mol Sci 2020 Sep 14;21(18).
    doi: 10.3390/ijms21186740pmc: PMC7554803pubmed: 32937917google scholar: lookup
  58. Beers JL, Fu D, Jackson KD. Cytochrome P450-Catalyzed Metabolism of Cannabidiol to the Active Metabolite 7-Hydroxy-Cannabidiol.. Drug Metab Dispos 2021 Oct;49(10):882-891.
    doi: 10.1124/dmd.120.000350pubmed: 34330718google scholar: lookup
  59. Chicoine A, Illing K, Vuong S, Pinto KR, Alcorn J, Cosford K. Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Cannabis Herbal Extract in Dogs.. Front Vet Sci 2020;7:583404.
    doi: 10.3389/fvets.2020.583404pmc: PMC7550466pubmed: 33134364google scholar: lookup
  60. Polidoro D, Temmerman R, Devreese M, Charalambous M, Ham LV, Cornelis I, Broeckx BJG, Mandigers PJJ, Fischer A, Storch J, Bhatti SFM. Pharmacokinetics of Cannabidiol Following Intranasal, Intrarectal, and Oral Administration in Healthy Dogs.. Front Vet Sci 2022;9:899940.
    doi: 10.3389/fvets.2022.899940pmc: PMC9215213pubmed: 35754531google scholar: lookup
  61. Hill AJ, Mercier MS, Hill TD, Glyn SE, Jones NA, Yamasaki Y, Futamura T, Duncan M, Stott CG, Stephens GJ, Williams CM, Whalley BJ. Cannabidivarin is anticonvulsant in mouse and rat.. Br J Pharmacol 2012 Dec;167(8):1629-42.
    doi: 10.1111/j.1476-5381.2012.02207.xpmc: PMC3525866pubmed: 22970845google scholar: lookup
  62. Borrelli F, Pagano E, Romano B, Panzera S, Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P, Izzo AA. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.. Carcinogenesis 2014 Dec;35(12):2787-97.
    doi: 10.1093/carcin/bgu205pubmed: 25269802google scholar: lookup
  63. De Caro C, Cristiano C, Avagliano C, Bertamino A, Ostacolo C, Campiglia P, Gomez-Monterrey I, La Rana G, Gualillo O, Calignano A, Russo R. Characterization of New TRPM8 Modulators in Pain Perception.. Int J Mol Sci 2019 Nov 7;20(22).
    doi: 10.3390/ijms20225544pmc: PMC6888553pubmed: 31703254google scholar: lookup
  64. Amstutz K, Schwark WS, Zakharov A, Gomez B, Lyubimov A, Ellis K, Venator KP, Wakshlag JJ. Single dose and chronic oral administration of cannabigerol and cannabigerolic acid-rich hemp extract in fed and fasted dogs: Physiological effect and pharmacokinetic evaluation.. J Vet Pharmacol Ther 2022 May;45(3):245-254.
    doi: 10.1111/jvp.13048pubmed: 35246858google scholar: lookup
  65. Colasanti BK. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol.. J Ocul Pharmacol 1990 Winter;6(4):259-69.
    doi: 10.1089/jop.1990.6.259pubmed: 1965836google scholar: lookup
  66. Deiana S. Potential medical uses of Cannabigerol: A brief Overview. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment Faculty of Life Sciences and Medicine, King’s College London, London, United Kingdom: Elsevier Science; (2017). 958–67.
  67. Li L, Li X, Xu L, Sheng Y, Huang J, Zheng Q. Systematic evaluation of dose accumulation studies in clinical pharmacokinetics.. Curr Drug Metab 2013 Jun;14(5):605-15.
    doi: 10.2174/13892002113149990002pubmed: 23701162google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.